Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems Ceases Development of Prostate Cancer Dx

NEW YORK (GenomeWeb News) – Australian firm Proteome Systems said today that it has stopped developing a protein biomarker-based test for prostate cancer because “the project did not satisfy internal assessment hurdles.”
The company said that it recently validated data generated by Egenix, which demonstrated that there is an increased expression of human carcinoma antigen in cancerous versus non-cancerous prostate tissues. The proof of concept study was aimed at evaluating the possibility of using a protein biomarker that provides specific detection of HCA in a semen-based test for prostate cancer.
However, Proteome Systems said that bringing the assay to market “would require significant resources along with an extended development timeline.”
The firm has a collaboration with Becton Dickinson to develop protein biomarkers for tuberculosis diagnostic products and an alliance with Bayer CropScience to use the firm’s DiagnostIQ device in defined agricultural fields.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.